

Guidelines on Bladder Cancer[☆]

Willem Oosterlinck^{a,*}, Bernard Lobel^b, Gerhard Jakse^c, Per-Uno Malmström^d,
Michael Stöckle^e, Cora Sternberg^f

The EAU Working Group on Oncological Urology^{☆☆}

^aDepartment of Urology, University Hospital Ghent, De Pintelaan 185, B-9000 Ghent, Belgium

^bCHRU Pontchaillou, Rennes, France

^cUniversity Clinics RWTH, Aachen, Germany

^dUniversity Hospital, Uppsala, Sweden

^eUniversity Saarland, Homburg, Saar, Germany

^fClinic Pio XI, Rome, Italy

Abstract

Objectives: On behalf of the European Association of Urology (EAU) guidelines for diagnosis, therapy and follow-up of bladder cancer patients were established. Criteria for recommendations were evidence based, and included aspects of cost-effectiveness and clinical feasibility.

Method: A systematic literature research using Medline Services was conducted. References were weighted by a panel of experts.

Results: TNM 1997 classification and WHO grading 1998 are recommended. Recommendations are developed for diagnosis for bladder cancer in general, treatment of superficial and infiltrative bladder cancer, and follow-up after different types of treatment modalities, such as intravesical instillations, radical cystectomy, urinary diversions, radiotherapy and chemotherapy.

© 2002 Elsevier Science B.V. All rights reserved.

Keywords: Bladder cancer; Superficial bladder cancer; Guidelines

1. Classification of bladder cancer

The use of the TNM classification 1997 and WHO grading, 1999, is encouraged, as it corresponds best with the clinical outcome of the tumours [1].

More than 90% of bladder cancers are transitional cell carcinoma (TCC); the remainder are squamous cell or adenocarcinoma.

Bladder tumours are considered superficial (TIS-Ta-T1) or infiltrative (T2-T3-T4) based on cystoscopy,

transurethral resection (TUR), imaging studies and histopathological findings.

There is also important inter observer variability in classifying stage T1 versus Ta tumours and grading tumours [2].

2. Diagnosis

2.1. Early detection

Early symptom recognition in bladder tumours is a key to better prognosis [6,7]. Haematuria is the most common finding in bladder cancer. The degree of haematuria does not correlate with the extent of the disease.

Bladder cancer may also present with voiding irritability.

2.2. Imaging

Intravenous pyelography is considered as an important examination to evaluate haematuria but the necessity to perform routinely is now questioned because of the low incidence of important findings obtained [3]. Ultrasonography combined with plain

[☆]For more extensive information consult the EAU Guidelines presented at the XVI EAU Annual Congress, Geneva, Switzerland (ISBN: 90-806179-3-9).

^{☆☆}EAU Working Group on Oncological Urology (Chairman: Prof. Dr. C.C. Abbou): Members of the EAU Working Group on Oncological Urology are the EAU Working Groups on Bladder Cancer, Penile Cancer, Prostate Cancer and Testis Cancer.

*Corresponding author. Tel. +32-9-240-2276; Fax: +32-9-240-3889.

E-mail address: willem.oosterlinck@rug.ac.be (W. Oosterlinck).

abdominal film was found to be as accurate in the diagnosis of the cause of haematuria as IVP.

Computed tomography scanning may be part of the evaluation of invasive bladder tumours and the evaluation of pelvic and abdominal lymph node metastasis. Its usefulness in predicting the local extent of the disease is reduced by artefactual abnormalities in the perivesical tissues.

The significance of routine bone scans before total cystectomy in infiltrative tumours is questionable.

2.3. Urinary cytology

Examination of a voided urine or bladder barbotage specimen for exfoliated cancer cells is particularly useful when a high-grade malignancy or CIS is present. It remains often negative in low-grade tumours.

2.4. Cystoscopy and TUR

A bimanual examination should be performed first to assess whether or not a mass is palpable in the bladder and, if so, whether it is fixed to the pelvic wall. TUR of the bladder tumour should be done so as to maximise the preservation of architectural detail and the relation of the tumour to the various layers of the bladder wall.

The more superficial component of the tumour should be resected separately from its deeper component.

Biopsy specimens of the tumour and suspected area should be taken to map the extent of the disease. Random biopsies of normal mucosa are indicated in the presence of positive cytology, even in the absence of a tumour, or in any non-papillary tumour. Random biopsies in patients with solitary papillary lesions are not indicated because of the absence of additional information [4] and because it may be noxious, as lesions to the mucosa can provoke implantation of tumour cells. Prostatic urethra biopsies by TUR are indicated for suspicion of TIS of the bladder in view of the high frequency of involvement of the prostatic urethra [5].

3. Treatment

- Ta-1 are superficial bladder tumours. Treatment will be directed towards the prevention of recurrence and progression of the disease.
- T1G3 has a high tendency to progression. The role of early cystectomy still is a matter of debate.
- TIS is a potential highly malignant disease that can still be treated in the majority of cases with bladder instillations of BCG. A cystectomy is necessary when this fails to cure the disease after two cycles of six weekly instillations.
- Tumours of T2 or higher category are infiltrating tumours and cystectomy will be necessary in the majority of cases. Bladder preservation can be an option in selected cases.
- N+ and metastatic diseases needs additional therapeutic approaches.

3.1. Treatment of Ta and T1 lesions

The therapeutic regimen for a Ta and T1 tumour will take into account the risk of recurrence and

progression, side effects and cost-effectiveness. The recurrence rate of superficial bladder cancer (SBC), even after adequate treatment, is widely documented [6,7]. The risk of progression to invasive cancer is low in the majority of cases, but goes up to 50% in high-grade T1G3 [7,8], which represents around 10% of cases.

The risk of recurrence and progression can be predicted on the basis of clinical and pathological data.

3.1.1. Prognostic factors

The prognostic factors for recurrence (in descending importance) [9,10] are the following.

1. The number of tumours present at diagnosis.
2. Recurrence rate in the previous period; a recurrence at 3 months.
3. Size of the tumour: the larger the tumour, the higher the risk of recurrence.
4. Anaplasia grade of the tumour.

For evolution to invasive disease, anaplasia grade and the T-category are of outmost importance.

Based on the prognostic factors, SBC can be divided into the following risk groups:

- Low-risk tumours: single, Ta, G1, ≤ 3 cm diameter.
- High-risk tumours: T1, G3, multifocal or highly recurrent, CIS (TIS).
- Intermediate: all other tumours, Ta-1, G1-2, multifocal, >3 cm diameter.

Immediate instillation after TUR with a chemotherapeutic agent should be encouraged in all cases as it is able to reduce recurrence rate by about 50% [11,12]. In intermediate risk tumours that needs a further instillation, an early instillation can reduce the need for maintenance therapy [13]. Low-risk tumours need no further treatment.

Tumours with a higher risk of recurrence should be treated with a 4–8-week-course of bladder instillation. Severe bladder irritation is a reason to delay or stop the treatment to avoid invalidating symptoms for the patient and later bladder contraction. Side effects are related to the intensity of the treatment regimen.

The usefulness of repeated instillations with chemotherapeutic agents is not clearly defined.

There is no proof that chemotherapeutic instillations longer than 6 months are worthwhile, if no recurrence is noticed. Intravesical therapy may be effective mainly by reducing the hazard of recurrence in the first phase after therapy.

On recurrence, the initial instillation schedule is restarted. In case of highly recurrent SBC or multiple recurrences it is advocated to change to BCG therapy

because of its proven results in these circumstances [14]. Progression of T1 tumours involves muscle infiltration and should be treated accordingly.

3.1.2. BCG

It has been found more effective in high-risk SBC BCG is able to prevent progression.

Six weekly induction instillations of BCG are necessary to provoke an immunological response and three cycles are necessary as a booster to obtain the same immunological reaction. In papillary T1-a G1-2 lesions, one can reduce the dose to 25% with the same effectiveness as the full dose and less general side effects [15].

BCG is not indicated in low-risk groups in which the potential danger of BCG does not counterbalance its advantage.

Lower recurrence rates have been reported after maintenance therapy of up to 3 years [14]. Whether or not this heavy schedule is necessary for all patients is uncertain.

3.2. Treatment of TIS

Standard treatment of TIS consists of BCG instillations given over a 6-week-period. Complete remission is obtained in up to 70% of cases. If cytology and biopsies remains positive, another cycle may produce an additional 15% complete remission. Maintenance therapy with booster cycles up to 36 months is advocated to prevent recurrence. If cure is not achieved after this second cycle or there is early recurrence, cystectomy with urethrectomy is indicated.

3.3. Treatment of T1G3 bladder tumours

The T1G3 bladder tumours have a high tendency to progress and therefore some experts tend to do early cystectomy. Nevertheless, it has been demonstrated that 50% of patients can conserve their bladder with bladder instillations of chemotherapeutic agents or BCG.

4. Treatment: radical cystectomy

Radical cystectomy is the standard treatment in most countries for muscle-invasive bladder tumour. However, renewed interest in quality-of-life issues has increased interest in bladder preservation treatments. But radiotherapy is still a choice in several countries. Also, performance status and age can influence the choice of therapy, with cystectomy being reserved for younger patients without concomitant disease.

4.1. Indications

The indication for cystectomy is a patient with muscle-invasive bladder cancer T2-T4a, N0-NX, M0. Other indications are patients with high-risk superficial tumours and BCG resistant TIS and T1G3 and extensive papillary disease that cannot be controlled with conservative measures.

4.2. Technique

Radical cystectomy consists of removal of the bladder and neighbouring organs, such as the prostate and seminal vesicles in men and uterus and adnexa in women. The distal part of the ureters is also usually resected and in cases with CIS a frozen section of the margin is advisable. The indications for urethrectomy are controversial. Currently, urethrectomy is recommended if the tumour involves the bladder neck in women and the prostatic urethra in men.

A radical cystectomy also includes a dissection of the regional lymph nodes, which will give valuable prognostic information. No controlled studies exist supporting the curative value of lymph node dissection [16]. Cystoscopy has a mortality from 1 to 4% and an important early morbidity. Late morbidity is nearly due to the urinary diversion.

The 5-year-survival rate is usually reported to be in the range of 40–60% and has not improved significantly in recent times. The use of pre-operative radio- or chemotherapy [17,18] has not changed the outcome.

Tumour stage and nodal involvement are the only independent predictors of survival [19].

5. Urinary diversion after radical cystectomy

Four alternatives are used presently after cystectomy, ileal conduit, continent pouch, a bladder reconstruction and ureterosigmoidostomy. The latter is only used in selected centres.

The ileal conduit is a reliable option with well-known good results. However, after long-term follow-up 20% develop stomal complications and 30% of the renal units become dilated [20].

A variety of continent reservoirs have been introduced, the majority of these used either ileal segments, ileocecal segments or the sigmoid colon [21]. Following continent urinary diversion early and late complications have been encountered in 12 and 37% of the patients, respectively [22]. Late complications seen included ureteral stricture/obstructions, incontinence, difficulty in catheterization, and urinary stones. Metabolic complications are common but in the majority of

cases, and with correct patient selection and education, problems may be minimised [23].

Orthotopic bladder replacement have been performed in men for more than a decade and in women more recently. The main advantage is that no stoma is necessary. Disadvantages include nocturnal leakage in one-third of the patients and problems with voiding requiring self-intermittent catheterization. As it concerns major surgery early and late complications remains frequent, requiring reoperation in about 22% of the patients [24].

Contra-indications to more complex procedures are debilitating neurological and psychiatric illnesses, short life expectancy and impaired liver or renal function. For continent urinary diversion the patient has to have the motivation and skill to learn self-catheterization. Contra-indications to orthotopic bladder substitutes are TCC of the prostatic urethra, widespread CIS, high-dose pre-operative irradiation, complex urethral stricture and intolerance to incontinence.

Studies of quality-of-life outcomes show that regardless of type of urinary diversion the majority of patients reported good overall quality-of-life, little emotional distress and few problems with social, physical or functional activities [25]. Problems with urinary diversion and sexual functioning were identified as the most common.

By many experts and several national guidelines, it is recommended to centralise continent pouch and bladder replacement operations in centres doing this intervention regularly, because this major surgery requires experience and teamwork.

6. Radiotherapy

Definitive radiotherapy with curative intent and the aim of bladder preservation is performed in T1–T4, N0, M0 transitional cell bladder cancer [26–29].

The decision for or against radiotherapy should be based on prognostic factors, patients desire and will be heavily influenced by the physician's preference [27,35].

Patients who are suitable for this treatment should have: adequate bladder capacity; normal bladder function; no recurrent urinary infections; previous inflammation or surgery of the true pelvis with consecutive adhesion [26,27].

External beam radiotherapy is the most common form of radiotherapy. The use of simultaneous chemotherapy to induce high control is investigated [30,31].

Brachytherapy is an alternative radiotherapeutic approach in selected patients with small solitary tumours of less than 5 cm in diameter [32].

6.1. Complications

The majority of patients undergoing radical radiation of the true pelvis will experience enteritis, proctitis, or "cystitis", which are usually easily controllable and self-limiting. Late toxic effects of significance are less prominent in modern series [28,29]. Erectile dysfunction will occur in more than two-thirds of male patients [33]. Sexual function in females seems not compromised [34].

6.2. Prognostic factors

Although the 5 year survival rate is acceptable, local recurrence will occur in about 50% of patients [28]. A small proportion of these patients can undergo salvage cystectomy [28,35].

7. Chemotherapy

Response rates of 40–70% with cisplatin-containing combination regimens have led to their use for the treatment of locally invasive disease in combination with cystectomy or radiotherapy, either as neo-adjuvant or adjuvant therapy [36–38].

Randomised trials with neo-adjuvant chemotherapy have not yet proven a survival benefit with neo-adjuvant chemotherapy [39]. However, response to chemotherapy is an important predictor of survival [40,41].

7.1. Neo-adjuvant chemotherapy and bladder preservation

Selected patients with invasive bladder tumours after neo-adjuvant chemotherapy may still have their bladders preserved, although the approach is highly controversial [41,42]. Bladder preservation may be possible with an integrated approach using chemotherapy and radiotherapy [43].

Prognostic factors for local curability were small tumour size, absence of hydronephrosis, papillary histology, visible complete TUR and a complete response to induction chemotherapy.

7.2. Adjuvant chemotherapy

Several trials with combination chemotherapy appeared to show a difference in favour of chemotherapy. Yet the results are controversial [44].

7.3. Metastatic disease

Two prospective randomised trials have proven the superiority of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) [45,46]. Unfortunately, the use of this combination chemotherapy is associated with

significant toxicity and produces long-term survival in only, approximately 15–20% of patients. The median survival duration is only 13 months and long-term survival is attained in, approximately 15% of patients with metastases in visceral sites and 30% of those with nodal disease.

Novel chemotherapeutic agents such as gemcitabine and the taxanes obtain similar overall survival, time to progressive disease, time to treatment failure, and response rate but gemcitabine + cisplatin appears to have a reduced toxicity profile compared to M-VAC [47,48].

The combination of gemcitabine and taxol has been shown to be highly effective in patients who have failed prior M-VAC [49]. When cisplatin gemcitabine and taxol were given to untreated patients, high overall response rates were observed [50].

7.4. Prognostic factors

The reported prognostic factors predictive of poor response to chemotherapy include elevated alkaline phosphatase level, age greater than 60 years and performance status [51].

8. Follow-up after TUR in SBC

Incomplete resection, implantation at traumatised sites in the bladder or rapid growth of epithelial malignancy are responsible for the higher recurrence rate of SBC after TUR at 3 months. Therefore, an early cystoscopy is advisable in all cases of SBC. In high-grade lesions (T1, G2 and 3), a second resection at the site of the TUR is advised earlier than 3 months [52].

8.1. Frequency of later cystoscopies

This should be adapted to the prognostic factors of the tumour. In low-risk tumours with no recurrence at 3 months, a follow-up cystoscopy can be delayed until 9 months later and then yearly up to 5 years because of the very low recurrence rate of the tumour [53]. In case of recurrence, the histological findings are the same as those of the primary TUR in over 95% of cases.

In patients with high-risk tumours, a cystoscopy every 3 months during the first 2 years remains the most commonly adapted follow-up schedule. Cystoscopy should then follow every 4 months in the third year, every 6 months thereafter for up to 5 years and then yearly. The schedule of follow-up in the intermediate group lies in between. With any recurrence, the schedule of cystoscopies is restarted from the beginning.

It seems advisable to stop follow-up in single TaG1 tumours in the absence of recurrence during 5 years. In

all other cases, yearly follow-up is advisable for up to 10 years, with lifelong follow-up for the high-risk group [54].

9. IVP

The development of an upper urinary tract tumour during follow-up of SBC is very rare, and therefore IVP should not be carried out routinely [55].

The highest frequency can be expected in CIS and therefore IVP should be carried out when cytology remains positive during follow-up [56,57].

10. Follow-up after radical cystectomy

The risk of tumour progression after radical cystectomy strongly depends on histopathological tumour stage [58]. Progression risk is highest within the first 24 months following cystectomy. Tumour progression may occur locally in the true pelvis, in regional or juxtaregional lymph nodes or as distant metastases. Furthermore, urothelial remnants in the upper tract and/or the urethra need to be checked for intraluminal tumour recurrences.

10.1. Therapeutic consequences of follow-up investigations (role of salvage therapy)

No prospective data are available for salvage treatment comparing asymptomatic tumour relapse. Patients with symptomatic tumour relapse often are characterised by a reduced general condition [59]. A reduced performance status is a predictor of a poor outcome. It does seem likely that efforts aiming at early detection of tumour progression may lead to an improved success rate of salvage therapy.

10.2. Anatomical sites

Of all cases with relapse, 15–20% are found in the true pelvis, another 10–15% in the pelvic or retroperitoneal lymph nodes. Local recurrences after cystectomy are reported for pT2a, 2b, and pT3 tumour at 6, 18 and 51%, respectively [60].

Distant metastases are mainly located in liver (38%), lung (36%) and bone (28%). More than 50% of all patients with tumour progression have distant metastases.

The most probable site of intraluminal disease recurrence is the male urethra, if it is not prophylactically removed at the time of the cystectomy. The incidence of a urethral recurrence is 5–13% [61]. Tumour involving the bladder neck or prostate and those with TIS are

at highest risk. Some contemporary series report a lower risk of urethral recurrences as compared to historical series [62].

Upper tract intraluminal recurrences are even less frequent, the cost-benefit of regular intravenous pyelo-

grams are limited by the low frequency of upper tract tumours and may therefore be partially replaced by ultrasound and urinary cytology [63].

Time schedule for follow-up after radical cystectomy and urinary diversion.

Time (min)	Mandatory	Optional
3	US ^a or IVP Blood Chem ^b Ph. Exam ^c	
6	Blood Chem Ph. Exam	CT Ch X-ray ^d urethra ^e
12	US or IVP Blood Chem Ph. Exam	CT Ch X-ray urethra
18	Blood Chem Ph. Exam	
24	US KUB ^f Blood Chem Ph. Exam	CT Ch X-ray urethra
36	Blood Chem Ph. Exam	CT Ch X-ray urethra
48	US KUB Blood Chem Ph. Exam	
60	Blood Chem Ph. Exam	Endoscopy urethra
72	US KUB Blood Chem Ph. Exam	Endoscopy urethra
96	US KUB Blood Chem Ph. Exam	Endoscopy urethra
120	US KUB Blood Chem Ph. Exam	Endoscopy urethra

^a US: ultrasound of the kidneys.

^b Blood Chem: liver and kidney tests, electrolytes, base excess (also vit. B12 after 4 years).

^c Ph. Exam: physical examination including DRE, endoscopy of bladder substitute or reservoir.

^d Ch X-ray: chest X-ray.

^e Urethra: scopy and/or wash.

^f KUB: plain abdominal X-ray.

References

- [1] Epstein J, Amin M, Reuter V, Mostofi F and the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. *Am J Surg Pathol* 1998;22:1435–48.
- [2] Tosini I, Wagner U, Sauter G, Egloff M, Knöggagil H, Alund G, Bannwart F, Mihatsg MJ, Gasser TC, Maurer R. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. *BJU Int* 2000;85:48–53.
- [3] Goessl C, Knispel HH, Miller K, Magnusson A. Is routine excretory urography necessary at first diagnosis of bladder cancer. *J Urol* 1997;157:480–1.
- [4] Vander Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta, T2 bladder tumours: A report from the EORTC GU Group. *Eur Urol* 1999;35:267–71.
- [5] Solsona E, Iborra IV, Mouros JL, Casanova JL, Almenar S. The prostate involvement as prognostic factor in patients with superficial bladder tumours. *J Urol* 1995;154:1740–3.
- [6] Pawinsky A, Sylvester R, Kurth K, Bouffieux C, van der Meijden A, Pasnar MK, Bijnens L. A combined analysis of EORTC and MRC randomized clinical trials for the prophylactic treatment of Ta, T1 bladder cancer. *J Urol* 1996;156:1934–41.
- [7] Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani P, Fair W. The treated natural history of high-risk superficial bladder cancer: 15-year outcome. *J Urol* 1997;158:62–7.
- [8] Herr HW. Tumour progression and survival in patients with T1G3 bladder tumours: 15 years outcome. *Br J Urol* 1997;80:162–765.
- [9] Kurth KH, Denis L, Bouffieux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, Oosterlinck W. Factors affecting recurrence and progression in superficial bladder tumors. *Eur J Cancer* 1995;31A(11):1840–6.
- [10] Millan-Rodriguez F, Chécille-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. *J Urol* 2000;163:73–8.
- [11] Tolley DA, Parmar MKB, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Grigor KN, Hall RR, Hargrave TB, Munson K, Newling DW, Richar B, Robinson MR, Ros MB, Smith PH, Willic JL, Whelan P. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow-up. *J Urol* 1996;155:1233–8.
- [12] Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R and members of the European Organization for Research and Treatment of Cancer Genitourinary Group. A prospective European Organization for Research and Treatment of Cancer genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of Epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. *J Urol* 1993;149:749–52.
- [13] Bouffieux CH, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw H, Sylvester R. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 European organization for research and treatment of cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed. Instillations and short-term versus long-term treatment. *J Urol* 1995;153:934–41.
- [14] Lamm DL, Blumenstein B, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy G, Bohl RD, Grossman HB, Beck TM, Leimers JT, Crawford ED. Maintenance BCG immunotherapy for recurrent Ta, T1 and TIS transitional cell carcinoma of the bladder: A randomized SWOG group study. *J Urol* 2000;163:1124–9.

- [15] Mack D, Frick J. Low-dose BCG therapy in superficial high risk bladder cancer: A phase II study with the BCG strain, Connaught Canada. *Br J Urol* 1995;75:185–7.
- [16] Leissner J, Hohenfellner R, Thüroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder, significance for staging and prognosis. *BJU* 2000;85:817–23.
- [17] EORTC-GU Group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. *Lancet* 1999;354:533–40.
- [18] Hellsten S, Rintala E, Wahlqvist R, Malmstrom PU. Nordic prospective trials of radical cystectomy and neoadjuvant chemotherapy. The Nordic Cooperative Bladder Cancer Study Group. *Eur Urol* 1998;33(Suppl 4):35–8.
- [19] Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, Pagano F. Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort. *Urology* 1999;161:1494–7.
- [20] Neal DE. Complication of ileal conduit diversion in adults with cancer followed up for at least five years. *Br Med J* 1985;290:1695–7.
- [21] Benson MC, Olsson CA. Continent urinary diversion. *Urol Clin North Am* 1999;26:125–47.
- [22] Lampel A, Fisch M, Stein R, Schulz-Lampel D, Hohenfellner M, Eggersmann C, Hohenfellner R, Thüroff JW. Continent diversion with the Mainz pouch. *World J Urol* 1996;14:85–91.
- [23] Mills RD, Studer UD. Metabolic consequences of continent urinary diversion. *J Urol* 1999;161:1057–66.
- [24] Hautmann RE, de Petriconi R, Gottfried HW, Kleinschmidt K, Mattes R, Paiss T. The ileal neobladder: Complications and functional results in 363 patients after 11 years of follow-up. *J Urol* 1999;161:422–7.
- [25] Mansson A, Mansson W. When the bladder is gone: Quality of life following different types of urinary diversion. *World J Urol* 1999;17:211–8.
- [26] Fossa SD, Waehre H, Aass N, Jacobsen AB, Olsen DR, Ous S. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. *Cancer* 1993;15:3036–42.
- [27] Shipley WU, Van der Schueren E, Kitagawa T, Gospodarowicz MK, Fromhold M, Magno L, Mochizuki S, Van den Bogaert W and Van der Werf-Messing B. Guidelines for radiation therapy in clinical research in bladder cancer. In: Shipley WU., editor, *Developments in Bladder Cancer*, Alan R Liss, New York, 1986. pp. 109–21.
- [28] Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, Herman JG, Garnett G, Chua T, Duncar W. Radical radiotherapy for the muscle invasive transitional cell carcinoma of the bladder: Failure analysis. *J Urol* 1989;142:1448–54.
- [29] Pollack A, Zagars GK. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. *Semin Urol Oncol* 1996;14:86–95.
- [30] Coppin C, Gospodarowicz MK, James K, Tannock IF, Zee B, Casson J, Pater J, Sullivan LD. The NCI-Canada trial of concurrent cisplatin and radiotherapy for muscle invasive bladder cancer. *J Clin Oncol* 1996;14:2901–7.
- [31] Sauer R, Birkenhake S, Kých R, Wittekind C, Schrott KM, Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. *Int J Radiat Oncol Biol Phys* 1998;40:121–7.
- [32] Moonen LM, van Horenblas S, Van der Voet JC, Nuyten M, Bartelink H. Bladder conservation in selected T1G3 and muscle-invasive T2-T3a bladder carcinoma using combination therapy of surgery and iridium-192 implantation. *Br J Urol* 1994;74:322–7.
- [33] Little FA, Howard GCW. Sexual function following radical radiotherapy for bladder cancer. *Radiation Oncol* 1998;49:157–61.
- [34] Kachnic LA, Shipley WU, Griffin PP, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Combined modality treatment with selective bladder conservation for invasive bladder cancer: Long-term tolerance in the female patient. *Cancer J Sci Am* 1996;2:79–84.
- [35] Greven KM, Solin LJ, Hanks GE. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. *Cancer* 1990;65:908–12.
- [36] Sternberg CN, Calabró F. Chemotherapy and management of bladder tumors. *Br J Urol* 2000;85(5):599–610.
- [37] Sternberg CN, Raghavan D, Ohi Y. Neo-adjuvant and adjuvant chemotherapy in locally advanced disease: What are the effects on survival and prognosis. *Int J Urol* 1995;2(2):76–88.
- [38] Donat SM, Herr HW, Bajorin DF, Fair WR, Sogani PC, Russo P, Sheinfeld J, Scher I. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. *J Urol* 1996;156:368–71.
- [39] Anonymous. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. *Lancet* 1999;354:533–40.
- [40] Splinter TA, Scher HI, Denis L, Bulkowski R, Simon S, Klimberg I, Soloway M, Vogelzang NJ, Van Tinteren H, Herr H. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer–Genitourinary Group. *J Urol* 1992;147:606–8.
- [41] Sternberg CN, Pansadoro V, Calabró F, Marini L, van Rijn A, Carli PD, Giannarelli D, Platania A, Rossetti A. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. *Ann Oncol* 1999;10:1301–5.
- [42] Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder sparing surgery for invasive bladder cancer: Ten-year outcome. *J Clin Oncol* 1998;16(4):1298–301.
- [43] Sternberg CN, Calabró F. Neo-adjuvant chemotherapy in invasive bladder cancer. *World J Urol* 2001;19(2):94–8.
- [44] Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer. What we do not know and why? *Ann Oncol* 2000;11:851–6.
- [45] Logothetis CJ, Dexeus F, Finn L, Sella A, Amato RJ, Ayala AG, Kibourn RG. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. *J Clin Oncol* 1990;8:1050–5.
- [46] Loehrer P, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study. *J Clin Oncol* 1992;10:1066–73.
- [47] Sternberg CN. Gemcitabine in Bladder Cancer. *Semin Oncol* 2000;27:31–9.
- [48] von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez-Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Crul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000;18:3068–77.
- [49] Sternberg CN, Sella A, Calabró F, Pizzocaro G, Marini L. Second-line chemotherapy with every 2-week gemcitabine and paclitaxel in previously treated patients with transitional cell carcinoma. *J Urol* 2000;163:236.
- [50] Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, Saenz A, Lopez-Brea M, Font A, Nogue M, Bastus R, Climert MA, de la Cruz JJ, Albanell J, Banus JM, Gallardo E, Diaz-Rubio E, Cortes-Funes H, Baselga J. A phase I–II study of paclitaxel, cisplatin and gemcitabine in advanced transitional cell carcinoma of the urothelium. *J Clin Oncol* 2000;18:3247–55.
- [51] Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. *Cancer* 1991;67:1525–31.

- [52] Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early? *J Urol* 2001;165:808–10.
- [53] Morris SB, Gordon EM, Shearer RJ, Woodhouse CRJ. Superficial bladder cancer: For how long should a tumour-free patient have check cystoscopies? *Br J Urol* 1995;75:193–6.
- [54] Holmang S, Hedelin H, Anderstrom C, Johansson SL, Walzer Y, Soloway MS. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1, transitional cell cancer of the bladder followed for at least 20 years. *J Urol* 1995;153:1823–7.
- [55] Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson L. Long-term follow-up of a bladder carcinoma cohort: Routine follow-up urography is not necessary. *J Urol* 1998;160:45–8.
- [56] Solsona E, Iborra IV, Ricos JV, Dumont R, Casanova JL, Calabouig C. Upper urinary tract involvement in patients with bladder carcinoma in situ: Its impact on management. *Urology* 1997;49:347–52.
- [57] Millan-Rodriguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Huguet-Pérez J, Vicente-Rodriguez J. Upper urinary tract tumors after primary superficial bladder tumors: Prognostic factors and risk groups. *J Urol* 2000;164:1183–7.
- [58] Stöckle M, Wellek S, Meyenburg W, Voges GE, Fisher U, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: Prognostic impact of lymph node involvement. *Urology* 1996;48:868–75.
- [59] Sengelov L, Nielsen OS, Kamby C, von der Maase H. Platinum analogue combination chemotherapy, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors. *Cancer* 1995;76:1797–803.
- [60] Greven KM, Spera JA, Solin LJ, Morgan T, Hanks GE. Local recurrence after cystectomy alone for bladder carcinoma. *Cancer* 1992;69:2767–70.
- [61] Clark PB. Urethral carcinoma after cystectomy: The case for routine urethrectomy. *J Urol* 1984;90:173.
- [62] Freeman JA, Esrig D, Stein JP, Skinner DG. Management of the patient with bladder cancer: Urethral recurrence. *Urol Clin North Am* 1994;21:645–51.
- [63] Hastie KJ, Hamdy FC, Collins MC, Williams JL. Upper tract tumours following cystectomy for bladder cancer. Is routine intravenous urography worthwhile? *Br J Urol* 1991;67:29–31.